definiens: means the trade and assets comprising the compoun d development business of R&D using the Assets, including all trade and as sets related to i ) the compound known as V24343, a CB1 antagonist ; ii ) the compound known as CPI-444, an a denosine A2A receptor antagonist ; iii ) the compound known as CHR2797 ( tosedostat ), an aminopeptidase inhibito r ; iv ) the compound known as VER-250840, an oral Ch k-1 ; v ) the compound known as V158866, a FAAH inhibitor ; vi ) the compound known as V2006 ( vipadenant ), an adenosine A2A receptor antagonist ; and vii ) the com pound known as Luminespib ( AUY922 ), an iv Heat Shoc k Protein 90 inhibitor, but excluding the Excluded As sets ; and means the trade and assets of R&D relating to the research, development, manufacture, marketing, sale and distribution in th e US of Tuzistra ®, an extended release oral suspens ion branded as Tuzistra XR containing codeine polistirex and ch lorpheniramine polistirex, pursuant to the authorit y granted by the FDA under NDA Approval No.207768, programmes CC P-07, CCP-08, CCP-05 and CCP-06, the rights to which are held by Tris Pharma Inc ( or an Affiliate thereof ) and Moxatag ®, a once - daily tablet branded as Moxatag containing 775 mg of amoxicillin, pursuant to the a uthority granted by the FDA under NDA Approval No . 50 - 813 ( amoxicillin extended - release tablets ) by R&D wheth er directly or through a 3rd party manufacturer ( Tr is Pharma, Inc ) or distributor ( [COMPANY] Therapeutics, Inc )